SYS-6010 is under clinical development by CSPC Pharmaceutical Group and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SYS-6010’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SYS-6010 overview
SYS-6010 is under development for the treatment of advanced solid tumors, non-small cell lung cancer (NSCLC), squamous non-small cell lung carcinoma, breast cancer, colorectal cancer, head and neck cancer. It is administered through intravenous route. It acts by targeting cells expressing epidermal growth factor receptor (EGFR).
CSPC Pharmaceutical Group overview
CSPC Pharmaceutical Group (CSPC) is a pharmaceutical company, which provides innovative, generic and bulk drugs. The company manufactures, research and markets medicines and pharmaceutical related products. CSPC product portfolio includes capsules, tablets, injections, caffeine and antibiotics such as acarbose, penicillin sodium, cefazolin sodium and meropenem. The company offers its products for various diseases including ovarian cancer, breast cancer, hypertension and leukemia. Its drugs focus on major therapeutic areas such as neurology, diabetes, cardio-cerebrovascular, oncology and anti-infective. The company operates in the Americas, Europe and Asia. CSPC Pharma is headquartered in Shijiazhuang, Hebei, China.
For a complete picture of SYS-6010’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
